KDM1B Antibody
Description
Overview of KDM1B Antibody
KDM1B antibodies are monoclonal or polyclonal reagents that bind specifically to the KDM1B protein. They are validated for use in techniques such as Western blot (WB), flow cytometry (FC), and enzyme-linked immunosorbent assay (ELISA). Key properties include:
2.1. Cancer Biology
-
Oncogenic Role: KDM1B is overexpressed in breast, colorectal, and lung cancers, where it promotes tumor growth and chemoresistance by demethylating H3K4me1/me2 . Antibodies enable detection of KDM1B in cancer cell lines and patient tissues.
-
Stemness Regulation: In breast cancer, KDM1B overexpression enriches cancer stem cell (CSC) populations (e.g., CD44+/EpCAM-, ALDHhigh) and upregulates pluripotency markers (NANOG, SOX2) . Neutralizing KDM1B with inhibitors like tranylcypromine reduces CSC expansion .
2.2. Epigenetic Studies
-
Chromatin Remodeling: KDM1B antibodies facilitate ChIP-seq analyses to map KDM1B’s interaction with genes involved in stemness, DNA repair, and immune evasion .
-
Enzyme Activity: Studies show KDM1B demethylates H3K4 but not H3K9 or H3K27, distinguishing it from LSD1/KDM1A .
3.1. Mechanistic Insights
-
IFN-I → KDM1B Axis: Type I interferons (IFN-I) upregulate KDM1B during chemotherapy, driving CSC plasticity and immune escape. KDM1B inhibition blocks this process, improving tumor control in murine models .
-
Morphological Changes: Overexpression of KDM1B in MDA-MB-231 breast cancer cells induces cobblestone-like morphology and alters epigenetic modifiers (e.g., LSD1, HDAC1/2) .
3.2. Clinical Correlations
-
Prognostic Marker: High KDM1B expression correlates with poor survival in basal-like breast cancer and HER2-negative tumors .
-
Therapeutic Target: Preclinical data support combining KDM1B inhibitors (e.g., tranylcypromine) with immunogenic therapies to prevent CSC-driven relapse .
Technical Considerations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Studies have shown that LSD2 (KDM1B) promotes the growth of small cell lung cancer by indirectly upregulating TFPI2 expression through the mediation of DNMT3B expression or by regulating the demethylation of H3K4me1 in the promoter region of the TFPI2 gene. PMID: 29845195
- This review focuses on small-molecule inhibitors targeted at the two flavin adenine dinucleotide-dependent lysine demethylases, lysine-specific demethylases 1 and 2 (KDM1A and KDM1B), and examines how the inhibitors interact with the tertiary structures of these enzymes. PMID: 28277979
- Research indicates a crucial role for LSD2 (KDM1B) in regulating DNA methylation and gene silencing in breast cancer. PMID: 24924415
- KDM1B has been shown to act as an E3 ubiquitin ligase, inhibiting cancer cell growth by promoting the proteasomal degradation of OGT. PMID: 25773598
- Transcriptome and chromatin immunoprecipitation-sequencing analyses have revealed that LSD2 (KDM1B) represses genes involved in lipid influx and metabolism through demethylation of histone H3K4. PMID: 25624347
- Research has demonstrated the regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylases 1 and 2 (KDM1A and KDM1B). PMID: 25036127
- The zinc finger-SWIRM-oxidase domains are essential for KDM1B demethylase activity and the binding of FAD. PMID: 23266887
- Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. PMID: 20670891
